摘要
目的探讨^(131)I结合人工肝支持系统(ALSS)治疗甲状腺功能亢进症(简称甲亢)合并重型肝炎的临床价值。方法将43例甲亢合并重型肝炎患者按治疗方案分成2组:A 组为抗甲状腺药物(ATD)治疗组,B 组为^(131)I 治疗组;其中 B 组又分为2组:B1组为非 ALSS 组,B2组为 ALSS组。分别比较 A、B 组的治愈好转率和 B1、B2组的治愈率,并观察每次 ALSS 治疗后1周内甲状腺激素和肝功能各项指标变化情况。结果 B 组的治愈好转率(96.0%)明显高于 A 组(61.1%,P<0.05);B2组的治愈率(84.6%)明显高于 B1组(33.3%.P<0.05);每次 ALSS 治疗后甲状腺激素水平和肝功能各项指标均明显改善。结论迅速控制甲亢是治疗甲亢合并重型肝炎的关键;^(131)I 治疗较 ATD 更为有效;ALSS 可提高^(131)I 治疗的治愈率和安全性。
Objective To assess the clinical application of ^131I and artificial liver support system （ALSS） in the treatment of hyperthyroidism complicated with severe hepatitis. Methods Forty-three hyperthyroidism patients complicated with severe hepatitis were divided into two groups： 18 cases treated with anti-thyroid drugs （ATD） as group A, and 25 cases with ^131I therapy as group B, the group B was further divided into： 12 cases were treated without ALSS as group B1, while 13 cases with AISS as in group B2. The cure and improved rates were compared between group A and B, and the cure rates were compared between group B1 and B2, respectively. Moreover, the changes of serum level of thyroid and liver function indexes before and 1 week after each AISS therapy were observed. Results The cure and improved rate of group B （96.0%） was significantly higher than that of group A （61.1%）, and the cure rate of group B2 （84.6%） was significantly higher than that of group B1 （33.3%, P 〈0.05 ）. Serum level of FT3, FT4, total bilirubin （TBIL）, direct bilirubin （DBIL）, aspartate aminotransferase （AST） and alanine aminotransferase （ALT） improved obviously after ALSS therapy （ P 〈 0.05 ）. Conclusions Rapid control hyperthyroidism is the key point in the treatment of hyperthyroidism complicated with severe hepatitis, and comparing with ATD, ^131I is more effective. Besides, ALSS is safe, and it can improve cure rate.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2006年第2期115-117,共3页
Chinese Journal of Nuclear Medicine
